6 days Ago By ABMN Staff
Alliancebernstein L.P. trimmed its holdings in shares of Arcellx, Inc.
( NASDAQ:ACLX – Free Report ) by 10.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,250 shares of the company’s stock after selling 6,181 shares during the period.
Alliancebernstein L.P.’s holdings in Arcellx were worth $3,930,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. KBC Group NV increased its holdings in Arcellx by 37.3% during the fourth quarter.
KBC Group NV now owns 1,388 shares of the company’s stock worth $106,000 after buying an additional 377 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Arcellx during the 4th quarter valued at approximately $184,000. Kazazian Asset Management LLC purchased a new stake in shares of Arcellx during the 4th quarter worth approximately $204,000.
Xponance Inc. raised its holdings in shares of Arcellx by 8.6% in the 4th quarter.
Xponance Inc. now owns 3,088 shares of the company’s stock worth $237,000 after purchasing an additional 244 shares during the period. Finally, Cibc World Markets Corp bought a new stake in shares of Arcellx in the 4th quarter worth approximately $309,000.
96.03% of the stock is owned by hedge funds and other institutional investors. Arcellx Trading Up 1.
9 % Shares of NASDAQ ACLX opened at $60.30 on Tuesday. The firm has a market cap of $3.
31 billion, a price-to-earnings ratio of -84.93 and a beta of 0.33.
The stock has a fifty day simple moving average of $65.27 and a two-hundred day simple moving average of $75.74.
Arcellx, Inc. has a 1-year low of $47.88 and a 1-year high of $107.
37. Insiders Place Their Bets In other Arcellx news, insider Rami Elghandour sold 38,300 shares of the business’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $62.
02, for a total transaction of $2,375,366.00. Following the sale, the insider now owns 149,186 shares of the company’s stock, valued at $9,252,515.
72. The trade was a 20.43 % decrease in their position.
The sale was disclosed in a legal filing with the SEC, which is available through this link . Also, Director Kavita Patel sold 1,500 shares of the stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $57.
50, for a total value of $86,250.00. The disclosure for this sale can be found here .
Insiders sold 54,455 shares of company stock worth $3,408,458 over the last quarter. 6.24% of the stock is currently owned by company insiders.
Arcellx Profile ( Free Report ) Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). Further Reading Want to see what other hedge funds are holding ACLX? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Arcellx, Inc. ( NASDAQ:ACLX – Free Report ). Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.
com's FREE daily email newsletter ..
